Cyclopropane Mitofusin Activators for Neurodegenerative Disease
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
There is a need for new compounds that target mitofusins to address mitochondrial dysfunction associated with neurodegenerative diseases, as aberrant mitofusin activity contributes to diseases like Charcot-Marie-Tooth disease, amyotrophic lateral sclerosis, and Huntington's disease.
Innovation Solution
Development of specific N-(cycloalkyl or heterocycloalkyl)-6-phenylhexanamide compounds, such as N-((1r,4r)-4-hydroxycyclohexyl)-2-(3-phenylpropyl)cyclopropane-1-carboxamide, which act as potent mitofusin activators, improving plasma half-life and neurological bioavailability by introducing rigidity into the methylene chain.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Duration of action of stationary object
If rigidity is introduced into the methylene chain of mitofusin activator compounds, then plasma half-life and neurological bioavailability are improved, but molecular flexibility and adaptability are reduced
Solution Approach 1:
The patent applies parameter changes by modifying the chemical structure of mitofusin activator compounds, specifically introducing rigidity into the methylene chain through cyclopropane rings or other rigidifying groups. This structural parameter change increases plasma half-life and neurological bioavailability while maintaining the compound's ability to activate mitofusin through optimized spatial arrangement of functional groups.
2Adaptability or versatility
If new compounds are developed to target mitofusins, then treatment options for mitochondrial dysfunction are expanded, but drug discovery complexity and development time increase
Solution Approach 1:
The patent applies segmentation by dividing the mitofusin activator compound into distinct functional modules: a mitofusin-binding domain with specific stereochemistry, a linker region with controlled flexibility, and a pharmacophore group. This modular segmentation enables systematic optimization of each component's contribution to activity, selectivity, and pharmacokinetic properties, reducing overall drug discovery complexity.
Solution Approach 2:
The patent systematically varies key molecular parameters including stereochemical configuration at chiral centers, length and composition of methylene chains, and types of terminal functional groups. This parameter optimization approach enables identification of compounds with improved plasma half-life and neurological bioavailability while maintaining mitofusin activation activity.
3Reliability
If mitofusin activity is activated to promote mitochondrial fusion, then mitochondrial function is improved, but aberrant mitofusin activity contributing to neurodegenerative diseases is not addressed
Solution Approach 1:
The patent optimizes the stereochemical parameters and molecular structure of mitofusin activators to achieve selective activation of mitofusin under specific cellular conditions. The compounds are designed with specific chiral configurations and functional group arrangements that enable them to correct aberrant mitofusin activity associated with neurodegenerative diseases while promoting healthy mitochondrial fusion dynamics.
Data Source
AI summary
The present disclosure relates to compounds of Formula (I):or pharmaceutically acceptable salts thereof. The present disclosure also relates to uses of the compounds, e.g., in treating or preventing diseases, disorders, or conditions (e.g., associated with mitochondria).